ACM
KROS icon

Aquatic Capital Management’s Keros Therapeutics KROS Stock Holding History

Aquatic Capital Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,775
Closed -$69K – 1402
2025
Q1 		$69K Buy
+6,775
New +$78.7K ﹤0.01% 1109
2024
Q3 		– Sell
-1,200
Closed -$54.8K – 1361
2024
Q2 		$54.8K Buy
+1,200
New +$64.5K ﹤0.01% 998
2023
Q3 		– Sell
-2,200
Closed -$88K – 1461
2023
Q2 		$88K Sell
2,200
-200
-8% -$8.77K ﹤0.01% 882
2023
Q1 		$102K Buy
2,400
+2,200
+1,100% +$111K 0.01% 742
2022
Q4 		$9K Buy
+200
New +$9.34K ﹤0.01% 1223

Other funds holding KROS

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Aquatic Capital Management's KROS Position: Q2 2025 in Review

Aquatic Capital Management sold out of Keros Therapeutics (KROS) in Q2 2025, closing a stake of 6,775 shares — an estimated $69K sold.

Aquatic Capital Management first reported a position in KROS in Q4 2022 and held it in 5 quarters. The position peaked at $102K in Q1 2023. 139 funds tracked by Wall St. Rank hold KROS as of Q2 2025.

  • Aquatic Capital Management reported no remaining Keros Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Aquatic Capital Management sold 6,775 Keros Therapeutics shares in Q2 2025, an estimated $69K.
  • Aquatic Capital Management first reported a position in Keros Therapeutics in Q4 2022 and held it in 5 quarters.
  • Aquatic Capital Management's Keros Therapeutics position peaked at $102K in Q1 2023.
  • 139 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2025.

Based on Aquatic Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.